Loading...

We've got a brand new version of Simply Wall St! Try it out

Biome Grow

CNSX:BIO
Snowflake Description

Reasonable growth potential with mediocre balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
BIO
CNSX
CA$38M
Market Cap
  1. Home
  2. CA
  3. Pharmaceuticals & Biotech
Company description

Biome Grow Inc., through its subsidiaries, operates as a licensed producer of cannabis in Nova Scotia under Canada’s ACMPR. The last earnings update was 24 days ago. More info.


Add to Portfolio Compare Print
  • Biome Grow has significant price volatility in the past 3 months.
BIO Share Price and Events
7 Day Returns
-15%
CNSX:BIO
-5.9%
CA Pharmaceuticals
1.3%
CA Market
1 Year Returns
-
CNSX:BIO
-46.7%
CA Pharmaceuticals
-0.1%
CA Market
BIO Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Biome Grow (BIO) -15% 3% -26.9% - - -
CA Pharmaceuticals -5.9% -3.4% -24.8% -46.7% 217.3% 286.4%
CA Market 1.3% 4.2% 1.6% -0.1% 8.4% 5.7%
1 Year Return vs Industry and Market
  • No trading data on BIO.
  • No trading data on BIO.
Price Volatility
Industry
5yr Volatility vs Market

Value

 Is Biome Grow undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Biome Grow to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Biome Grow.

CNSX:BIO Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 1 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 6.8%
Perpetual Growth Rate 10-Year CA Government Bond Rate 1.9%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for CNSX:BIO
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year CA Govt Bond Rate 1.9%
Equity Risk Premium S&P Global 6%
Pharmaceuticals Unlevered Beta Simply Wall St/ S&P Global 0.7
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.698 (1 + (1- 26.5%) (3.33%))
0.809
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.81
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 1.95% + (0.809 * 5.96%)
6.77%

Discounted Cash Flow Calculation for CNSX:BIO using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Biome Grow is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

Note: Free cash flow to equity valuations ignore the company's cash or debt.

CNSX:BIO DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (CAD, Millions) Source Present Value
Discounted (@ 6.77%)
2020 7.36 Analyst x1 6.90
2021 27.92 Analyst x1 24.49
2022 43.41 Analyst x1 35.66
2023 50.14 Analyst x1 38.58
2024 55.09 Est @ 9.86% 39.70
2025 59.22 Est @ 7.49% 39.97
2026 62.67 Est @ 5.83% 39.62
2027 65.59 Est @ 4.66% 38.84
2028 68.11 Est @ 3.85% 37.77
2029 70.35 Est @ 3.28% 36.54
Present value of next 10 years cash flows CA$338.00
CNSX:BIO DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= CA$70.35 × (1 + 1.95%) ÷ (6.77% – 1.95%)
CA$1,486.83
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= CA$1,486.83 ÷ (1 + 6.77%)10
CA$772.24
CNSX:BIO Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= CA$338.00 + CA$772.24
CA$1,110.24
Equity Value per Share
(CAD)
= Total value / Shares Outstanding
= CA$1,110.24 / 110.57
CA$10.04
CNSX:BIO Discount to Share Price
Calculation Result
Value per share (CAD) From above. CA$10.04
Current discount Discount to share price of CA$0.34
= -1 x (CA$0.34 - CA$10.04) / CA$10.04
96.6%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Biome Grow is available for.
Intrinsic value
>50%
Share price is CA$0.34 vs Future cash flow value of CA$10.04
Current Discount Checks
For Biome Grow to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Biome Grow's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Biome Grow's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Biome Grow's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Biome Grow's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
CNSX:BIO PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-06-30) in CAD CA$-0.09
CNSX:BIO Share Price ** CNSX (2019-09-20) in CAD CA$0.34
Canada Pharmaceuticals Industry PE Ratio Median Figure of 13 Publicly-Listed Pharmaceuticals Companies 15.3x
Canada Market PE Ratio Median Figure of 539 Publicly-Listed Companies 14.14x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Biome Grow.

CNSX:BIO PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= CNSX:BIO Share Price ÷ EPS (both in CAD)

= 0.34 ÷ -0.09

-3.98x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Biome Grow is loss making, we can't compare its value to the CA Pharmaceuticals industry average.
  • Biome Grow is loss making, we can't compare the value of its earnings to the Canada market.
Price based on expected Growth
Does Biome Grow's expected growth come at a high price?
Raw Data
CNSX:BIO PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -3.98x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts
Not available
Canada Pharmaceuticals Industry PEG Ratio Median Figure of 7 Publicly-Listed Pharmaceuticals Companies 1.56x
Canada Market PEG Ratio Median Figure of 245 Publicly-Listed Companies 1.02x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Biome Grow, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Biome Grow's assets?
Raw Data
CNSX:BIO PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-06-30) in CAD CA$0.12
CNSX:BIO Share Price * CNSX (2019-09-20) in CAD CA$0.34
Canada Pharmaceuticals Industry PB Ratio Median Figure of 151 Publicly-Listed Pharmaceuticals Companies 2.36x
Canada Market PB Ratio Median Figure of 2,457 Publicly-Listed Companies 1.43x
CNSX:BIO PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= CNSX:BIO Share Price ÷ Book Value per Share (both in CAD)

= 0.34 ÷ 0.12

2.74x

* Primary Listing of Biome Grow.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Biome Grow is overvalued based on assets compared to the CA Pharmaceuticals industry average.
X
Value checks
We assess Biome Grow's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. Biome Grow has a total score of 2/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Biome Grow expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
147%
Expected annual growth in revenue.
Earnings growth vs Low Risk Savings
Is Biome Grow expected to grow at an attractive rate?
  • Biome Grow is expected to become profitable in the next 1-3 years, this is considered above the low risk savings rate of 1.9%.
Growth vs Market Checks
  • Unable to compare Biome Grow's earnings growth to the Canada market average as no estimate data is available.
  • Biome Grow's revenue growth is expected to exceed the Canada market average.
Annual Growth Rates Comparison
Raw Data
CNSX:BIO Future Growth Rates Data Sources
Data Point Source Value (per year)
CNSX:BIO Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 1 Analysts 147%
Canada Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 97.7%
Canada Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 56.5%
Canada Market Earnings Growth Rate Market Cap Weighted Average 12.6%
Canada Market Revenue Growth Rate Market Cap Weighted Average 5.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
CNSX:BIO Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
All numbers in CAD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
CNSX:BIO Future Estimates Data
Date (Data in CAD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31 40 10 10 1
2019-12-31 11 -2 1
2019-09-22
CNSX:BIO Past Financials Data
Date (Data in CAD Millions) Revenue Cash Flow Net Income *
2019-06-30 2 -5 -9
2019-03-31 0 -5 -9
2018-12-31 -5 -9
2018-09-30 0 -3 -5
2018-06-30 0 -2 -2
2018-03-31 -2 -1
2017-12-31 -1 -1
2016-12-31 0 0

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Biome Grow is expected to become profitable in the next 1-3 years, this is considered high growth.
  • Biome Grow's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
CNSX:BIO Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below

All data from Biome Grow Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

CNSX:BIO Future Estimates Data
Date (Data in CAD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31 0.05 0.05 0.05 1.00
2019-12-31
2019-09-22
CNSX:BIO Past Financials Data
Date (Data in CAD Millions) EPS *
2019-06-30 -0.09
2019-03-31 -0.09
2018-12-31 -0.09
2018-09-30 -0.04
2018-06-30 -0.01
2018-03-31 -0.01
2017-12-31 -0.01
2016-12-31

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Biome Grow will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Biome Grow's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Canada market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Canada market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Biome Grow has a total score of 4/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Biome Grow performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Biome Grow's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Biome Grow does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.
  • Unable to compare Biome Grow's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Biome Grow's 1-year growth to the CA Pharmaceuticals industry average as it is not currently profitable.
Earnings and Revenue History
Biome Grow's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Biome Grow Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

CNSX:BIO Past Revenue, Cash Flow and Net Income Data
Date (Data in CAD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-06-30 1.68 -9.24 6.84
2019-03-31 0.34 -9.15 6.15
2018-12-31 -8.86 5.40
2018-09-30 0.00 -5.28 3.54
2018-06-30 0.01 -1.70 1.69
2018-03-31 -1.10 1.10
2017-12-31 -0.83 0.79
2016-12-31 0.00

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Biome Grow has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Biome Grow has efficiently used its assets last year compared to the CA Pharmaceuticals industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Biome Grow improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Biome Grow's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Biome Grow has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Biome Grow's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Biome Grow's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Biome Grow is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Biome Grow has no long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Biome Grow's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is covered by short term assets, assets are 2.5x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Biome Grow Company Filings, last reported 2 months ago.

CNSX:BIO Past Debt and Equity Data
Date (Data in CAD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-06-30 13.70 1.25 0.62
2019-03-31 14.40 0.50 0.74
2018-12-31 15.01 0.00 1.86
2018-09-30 15.01 0.00 1.86
2018-06-30 14.94 0.23 3.17
2018-03-31 9.78 0.00 3.07
2017-12-31 9.78 0.00 3.07
2016-12-31 0.00 0.00
  • Biome Grow's level of debt (9.1%) compared to net worth is satisfactory (less than 40%).
  • Unable to establish if Biome Grow's debt level has increased without past 5-year debt data.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Biome Grow has less than a year of cash runway based on current free cash flow.
  • Unable to confirm if Biome Grow has at least 1 year of cash runway based on growing free cash flows without relevant data.
X
Financial health checks
We assess Biome Grow's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Biome Grow has a total score of 3/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Biome Grow's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Biome Grow dividends.
If you bought CA$2,000 of Biome Grow shares you are expected to receive CA$0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Biome Grow's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Biome Grow's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
CNSX:BIO Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
North America Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 10 Stocks 2.8%
Canada Market Average Dividend Yield Market Cap Weighted Average of 334 Stocks 3.5%
Canada Minimum Threshold Dividend Yield 10th Percentile 1.1%
Canada Bottom 25% Dividend Yield 25th Percentile 2%
Canada Top 25% Dividend Yield 75th Percentile 5.8%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

CNSX:BIO Future Dividends Estimate Data
Date (Data in CA$) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2019-12-31
2019-09-22

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Biome Grow has not reported any payouts.
  • Unable to verify if Biome Grow's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Biome Grow's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Biome Grow has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Biome Grow's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.1%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Biome Grow afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Biome Grow has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Biome Grow's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Khurram Malik
COMPENSATION CA$86,898
TENURE AS CEO 0.9 years
CEO Bio

Mr. Khurram Malik, MBA, serves as Chief Executive Officer and Director at Biome Grow Inc. since October 03, 2018. Mr. Malik serves as the President of Biome Grow Inc. He was a Clean Technology Analyst at Jacob Securities Inc., Research Division. He focused on renewable and efficient technology companies at the firm. Prior to this, Mr. Malik has one year of Canadian sell-side research experience in special situations at independent investment dealer, and four years of sell-side research experience at Morgan Stanley, Research Division. Mr. Malik serves as Chief Executive Officer and Director at Biome Grow Inc. He holds a MBA degree.

CEO Compensation
  • Insufficient data for Khurram to compare compensation growth.
  • Khurram's remuneration is lower than average for companies of similar size in Canada.
Management Team Tenure

Average tenure of the Biome Grow management team in years:

0.9
Average Tenure
  • The average tenure for the Biome Grow management team is less than 2 years, this suggests a new team.
Management Team

Khurram Malik

TITLE
CEO, President & Director
COMPENSATION
CA$87K
TENURE
0.9 yrs

Abbey Abdiye

TITLE
Chief Financial Officer
COMPENSATION
CA$25K
TENURE
0.9 yrs

George Smitherman

TITLE
Senior VP of Corporate Affairs & Director
COMPENSATION
CA$160K
TENURE
0.5 yrs

Laird Choi

TITLE
Vice President of Corporate Services
COMPENSATION
CA$118K

Frank MacMaster

TITLE
President of Highland Grow Inc.
COMPENSATION
CA$231K

David Callahan

TITLE
President of The Back Home Medical Cannabis Corporation
COMPENSATION
CA$145K

Scott Cuthbertson

TITLE
VP of Investor Relations
Board of Directors Tenure

Average tenure of the Biome Grow board of directors in years:

0.9
Average Tenure
  • The average tenure for the Biome Grow board of directors is less than 3 years, this suggests a new board.
Board of Directors

Khurram Malik

TITLE
CEO, President & Director
COMPENSATION
CA$87K
TENURE
0.9 yrs

George Smitherman

TITLE
Senior VP of Corporate Affairs & Director
COMPENSATION
CA$160K
TENURE
0.9 yrs

Brett James

TITLE
Director
COMPENSATION
CA$160K
TENURE
0.9 yrs

J. Lievonen

TITLE
Director
COMPENSATION
CA$160K
TENURE
0.9 yrs

Steven Poirier

TITLE
Director
COMPENSATION
CA$160K
AGE
64
TENURE
0.9 yrs

Rita Theil

TITLE
Independent Director
TENURE
0.3 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (CA$) Value (CA$)
18. Mar 19 Buy George Smitherman Individual 15. Mar 19 15. Mar 19 34,000 CA$0.63 CA$20,120
04. Mar 19 Buy George Smitherman Individual 01. Mar 19 01. Mar 19 2,235 CA$0.70 CA$1,564
20. Feb 19 Buy George Smitherman Individual 19. Dec 18 19. Dec 18 18,000 CA$0.75 CA$13,500
X
Management checks
We assess Biome Grow's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Biome Grow has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Biome Grow (CNSX:BIO) May Be Weighed Down By Its Debt

CNSX:BIO Historical Debt, July 30th 2019 How Healthy Is Biome Grow's Balance Sheet? … According to the balance sheet data, Biome Grow had liabilities of CA$910.4k due within 12 months, but no longer term liabilities. … If you're interested in investing in businesses that can grow profits without the burden of debt, then check out this free list of growing businesses that have net cash on the balance sheet.

Simply Wall St -

What Kind Of Investor Owns Most Of Biome Grow Inc. (CNSX:BIO)?

If you want to know who really controls Biome Grow Inc. … Insiders often own a large chunk of younger, smaller, companies while huge companies tend to have institutions as shareholders. … With a market capitalization of CA$56m, Biome Grow is a small cap stock, so it might not be well known by many institutional investors.

Simply Wall St -

Company Info

Description

Biome Grow Inc., through its subsidiaries, operates as a licensed producer of cannabis in Nova Scotia under Canada’s ACMPR. It also operates a virtual reality technology platform that focuses on the medical and recreational cannabis markets. The company is headquartered in Toronto, Canada.

Details
Name: Biome Grow Inc.
BIO
Exchange: CNSX
Founded:
CA$37,593,567
110,569,315
Website: http://www.biomegrow.com
Address: Biome Grow Inc.
480 University Avenue,
Suite 1401,
Toronto,
Ontario, M5G 1V2,
Canada
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
CNSX BIO New Common Shares Canadian National Stock Exchange CA CAD 09. Oct 2018
OTCPK BIOI.F New Common Shares Pink Sheets LLC US USD 09. Oct 2018
DB 6OTA New Common Shares Deutsche Boerse AG DE EUR 09. Oct 2018
MUN 6OTA New Common Shares Boerse Muenchen DE EUR 09. Oct 2018
Number of employees
Current staff
Staff numbers
0
Biome Grow employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/09/22 00:40
End of day share price update: 2019/09/20 00:00
Last estimates confirmation: 2019/09/12
Last earnings filing: 2019/08/29
Last earnings reported: 2019/06/30
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.